Does Nevada Medicaid Cover Wegovy or Zepbound?
Nevada (NV) GLP-1 access depends on three state-specific policy questions before it ever gets to pricing: does Nevada Medicaid cover weight-loss GLP-1s, has Nevada expanded Medicaid under the ACA, and does the state employee health plan cover them. Answering those first tells you whether you're likely working with insurance or planning for cash-pay.
Nevada Medicaid GLP-1 coverage: what the state's own documents say
Nevada Medicaid's manual approves an incretin mimetic only if it 'is not being prescribed for weight loss in absence of T2DM indication', with one Wegovy exception for cardiovascular risk reduction in non-diabetic adults 18 and older with established cardiovascular disease plus obesity or overweight (prior authorization, specialist-verified).
Checked September 20, 2026 against: nevadamedicaid.nv.gov, medicaid.nv.gov, medicaid.nv.gov.
Nevada state employee health plan: what the plan's own documents say
Nevada's PEBP master plan documents (plan years 2026 and 2027) exclude anti-obesity branded products and cover only certain short-term generic weight-loss drugs, and only for members in the voluntary Obesity Care Management Program (BMI over 30, or over 25 with a listed comorbidity); Wegovy, Zepbound, Saxenda, oral Wegovy and Foundayo are therefore not covered for weight loss.
Checked September 20, 2026 against: pebp.nv.gov, pebp.nv.gov, pebp.nv.gov.
Notable insurers active in Nevada (not independently verified): Anthem Blue Cross Blue Shield, Health Plan of Nevada, Hometown Health.
Why GLP-1 coverage varies this much by state
Medicaid is a state-federal partnership, not a single national program. Each state Medicaid agency sets its own preferred drug list (PDL) and prior-authorization criteria within federal minimum requirements. Weight-loss drugs are not a federally mandated Medicaid benefit, so states choose independently whether to cover them - which is why only 10 of 50 states currently do (Nevada is not one of them).
State employee health plans are a useful bellwether. These plans cover hundreds of thousands of state workers and negotiate directly with pharmacy benefit managers, so their coverage decisions often signal where commercial insurers in that state are heading. North Carolina's State Health Plan, for example, ended coverage of weight-loss GLP-1s on April 1, 2024, after its board voted 4-3 to cut it citing the drugs' high cost - a case that other states and large employers have watched closely.
Medicaid expansion status shapes who even has coverage to begin with. States that haven't adopted ACA Medicaid expansion have narrower Medicaid eligibility overall, which - combined with the weight-loss GLP-1 exclusion most states apply regardless of expansion status - pushes a larger share of residents in those states toward commercial insurance, telehealth, or manufacturer self-pay as their only realistic path.
National reference pricing (same nationwide - your actual cost depends on your plan)
These prices are the same across all 50 states because manufacturer list prices, self-pay programs, and telehealth pricing don't vary by state - only insurance coverage and copay do, which is why the Nevada-specific policy facts above matter more than the table below for predicting your actual cost.
| Drug | Covered by insurance | Manufacturer self-pay | Telehealth | Cash retail |
|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $1,349 |
| Ozempic 11.6% weight loss | $63 | - | $399 | $1,028 |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 | $449 | $1,349 |
| Zepbound 22.5% weight loss | $88 | $299 | $499 | $1,059 |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $1,069 |
| Saxenda 8.4% weight loss | $63 | - | $399 | $1,349 |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 | - | $1,099 |
| CagriSema 20.4% weight loss | $88 | $599 | - | $1,499 |
Cheapest cash-pay GLP-1 paths for Nevada residents
Manufacturer direct prices (LillyDirect, NovoCare) are usually cheapest. Updated May 2026.
| Drug | Insurance | Mfr direct | Telehealth (brand) | Telehealth (compd) | Cash retail | Get it |
|---|---|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $249 cheapest | $1,349 | Get →ad |
| Ozempic 11.6% weight loss | $63 | - | $399 | $199 cheapest | $1,028 | Get →ad |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 cheapest | $449 | - | $1,349 | Get →ad |
| Zepbound 22.5% weight loss | $88 | $299 cheapest | $499 | $299 cheapest | $1,059 | Get →ad |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $299 cheapest | $1,069 | Get →ad |
| Saxenda 8.4% weight loss | $63 | - | $399 cheapest | - | $1,349 | Get →ad |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 cheapest | - | - | $1,099 | Get →ad |
Nevada carrier coverage details
National carriers active in Nevada (this list is not independently verified). Drill into each carrier's prior-auth requirements, formulary, and appeal playbook.
Frequently asked questions
Does Nevada Medicaid cover Wegovy or Zepbound for weight loss?
No. Nevada Medicaid's manual approves an incretin mimetic only if it 'is not being prescribed for weight loss in absence of T2DM indication', with one Wegovy exception for cardiovascular risk reduction in non-diabetic adults 18 and older with established cardiovascular disease plus obesity or overweight (prior authorization, specialist-verified). This was checked against Nevada's own documents on September 20, 2026; coverage rules change often, so confirm with your plan before relying on it. Coverage for type 2 diabetes (Ozempic, Mounjaro) is a separate question. Medicare's GLP-1 Bridge, which started July 1, 2026, works separately from Medicaid and applies in every state.
Has Nevada expanded Medicaid under the ACA?
Yes - Nevada has adopted Medicaid expansion, which broadens who qualifies for Medicaid coverage generally, though it does not by itself guarantee GLP-1 weight-loss coverage (see above).
Does the Nevada state employee health plan cover Wegovy or Zepbound?
No. Nevada's PEBP master plan documents (plan years 2026 and 2027) exclude anti-obesity branded products and cover only certain short-term generic weight-loss drugs, and only for members in the voluntary Obesity Care Management Program (BMI over 30, or over 25 with a listed comorbidity); Wegovy, Zepbound, Saxenda, oral Wegovy and Foundayo are therefore not covered for weight loss. This was checked against Nevada's own plan documents on September 20, 2026; plan terms are reset each plan year, so confirm with your plan before relying on it.